Genetic polymorphisms of FcγRIIa and FcγRIIIa are not predictive of clinical outcomes after cetuximab plus irinotecan chemotherapy in patients with metastatic colorectal cancer

Oncology

Volumn 82, Issue 2, 2012, Pages 83-89

  Park, Seong Joon ^a   Hong, Yong Sang ^a   Lee, Jae Lyun ^a   Ryu, Min Hee ^a   Chang, Heung Moon ^a   Kim, Kyu Pyo ^a   Ahn, Yong Chel ^a   Na, Young Soon ^a   Jin, Dong Hoon ^a   Yu, Chang Sik ^a   Kim, Jin Cheon ^a   Kang, Yoon Koo ^a   Kim, Tae Won ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Biomarker; Cetuximab; Colorectal cancer; Fc receptor polymorphism; KRAS mutation

Indexed keywords

CETUXIMAB; FC RECEPTOR; FC RECEPTOR IIA; FC RECEPTOR IIIA; FLUOROURACIL; FOLINIC ACID; GENOMIC DNA; IRINOTECAN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; ONCOGENE K RAS; OVERALL SURVIVAL; PERITONEUM METASTASIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE; WILD TYPE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; POLYMORPHISM, GENETIC; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTORS, IGG;

EID: 84862822870     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000335959     Document Type: Article

References (31)

1. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A, Vauthey JN, Nagorney DM, McWilliams RR: Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009; 27: 3677-3683.
2. Chau I, Cunningham D: Treatment in advanced colorectal cancer: what, when and how? Br J Cancer 2009 100 1704-1719.
3. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417.
4. Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J, Lenz HJ, Borg C, Middleton G, Kroning H, Luppi G, Kisker O, Zubel A, Langer C, Kopit J, Burris HA 3rd: EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 2311-2319.
5. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ: Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 2040-2048. (Pubitemid 350106711)
6. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345. (Pubitemid 38944402)
7. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, Van Cutsem E, Tejpar S: KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008; 19: 508-515. (Pubitemid 351325672)
8. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboue R, Tuech JJ, Queuniet AM, Paillot B, Sabourin JC, Michot F, Michel P, Frebourg T: Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 2007; 96: 1166-1169. (Pubitemid 46625066)
9. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouche O, Landi B, Louvet C, Andre T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F, Laurent-Puig P: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26: 374-379. (Pubitemid 351171687)
10. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Cote JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992-3995.
11. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, Bardelli A: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6: 279-286. (Pubitemid 40590264)
12. Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, Camponovo A, Etienne LL, Cavalli F, Mazzucchelli L: PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007; 97: 1139-1145. (Pubitemid 47587019)
13. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26: 5705-5712.
14. Sohn BS, Kim TW, Lee JL, Ryu MH, Chang HM, Kang YK, Park HS, Na YS, Jang SJ, Kim JC, Lee JS: The role of KRAS mutations in predicting the efficacy of cetuximab-plusirinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients. Oncology 2009; 77: 224-230.
15. Herbst RS, Shin DM: Monoclonal antibodies to target epidermal growth factor receptorpositive tumors: a new paradigm for cancer therapy. Cancer 2002; 94: 1593-1611. (Pubitemid 34212655)
16. Kawaguchi Y, Kono K, Mimura K, Sugai H, Akaike H, Fujii H: Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer 2007; 120: 781-787. (Pubitemid 46175397)
17. Kurai J, Chikumi H, Hashimoto K, Yamaguchi K, Yamasaki A, Sako T, Touge H, Makino H, Takata M, Miyata M, Nakamoto M, Burioka N, Shimizu E: Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 2007; 13: 1552-1561. (Pubitemid 46450447)
18. Weiner GJ: Monoclonal antibody mechanisms of action in cancer. Immunol Res 2007; 39: 271-278. (Pubitemid 47574893)
19. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M: Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 1997; 90: 1109-1114. (Pubitemid 27314146)
20. Parren PW, Warmerdam PA, Boeije LC, Arts J, Westerdaal NA, Vlug A, Capel PJ, Aarden LA, van de Winkel JG: On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. J Clin Invest 1992; 90: 1537-1546.
21. Weng WK, Levy R: Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21: 3940-3947. (Pubitemid 46606207)
22. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, Neri TM, Ardizzoni A: Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008; 26: 1789-1796.
23. Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, Lamy A, Penault-Llorca F, Frebourg T, Michel P, Sa bourin JC, Boissiere-Michot F: Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009; 27: 1122-1129.
24. Pander J, Gelderblom H, Antonini NF, Tol J, van Krieken JH, van der Straaten T, Punt CJ, Guchelaar HJ: Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. Eur J Cancer 2010; 46: 1829-1834.
25. Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ: FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007; 25: 3712-3718. (Pubitemid 47372612)
26. Paez D, Pare L, Espinosa I, Salazar J, Del Rio E, Barnadas A, Marcuello E, Baiget M: Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy? Cancer Sci 2010 101 2048-2048.
27. Geva R, Jensen BV, Fountzilas G, Yoshino T, Paez D, Montagut C, Sougklakos I, Cappuzzo F, Cervantes-Ruiperez A, Papamichael D, Frattini M, Vincenzi B, Macarulla T, Loupakis F, Spindler KG, Qvortrup C, Ciardiello F, Tejpar S: An international consortium study in chemorefractory metastatic colorectal cancer (MCRC) patients (pts) to assess the impact of FCGR polymorphisms on cetuximab efficacy. J Clin Oncol 2011; 29(suppl):abstract 3528.
28. Zhang W, Yang D, Harbison C, Khambata-Ford S, Malone DP, Ning Y, Bohanes PO, Gerger A, Labonte MJ, Benhaim L, El-Khoueiry AB, Iqbal S, Lenz H: FCGR2A H131R and FCGR3A V158F polymorphism status in mCRC patients treated with singleagent cetuximab (IMCL 0144 and CA225045) or with second-line irinotecan plus cetuximab (EPIC): a pooled statistical analysis. J Clin Oncol 2011; 29(15 suppl):e14025.
29. Clynes RA, Towers TL, Presta LG, Ravetch JV: Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6: 443-446. (Pubitemid 30208162)
30. Markman B, Gomez-Roca C, Cervantes-Ruiperez A, Tabernero J: Phase I PK/PD study of RO5083945 (GA201), the first glycoengineered anti-EGFR monoclonal antibody (mAb) with optimized antibody dependent cellular cytotoxicity (ADCC). J Clin Oncol 2010; 28(suppl):abstract 2522.
31. Pedersen MW, Jacobsen HJ, Koefoed K, Hey A, Pyke C, Haurum JS, Kragh M: Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 2010; 70: 588-597.